1. Cell Cycle/DNA Damage Autophagy Apoptosis
  2. Topoisomerase Autophagy Apoptosis
  3. Topotecan

Topotecan  (Synonyms: SKF 104864A; NSC 609669)

Cat. No.: HY-13768
Handling Instructions

Topotecan (SKF 104864A; NSC 609669) is an orally active and potent Topoisomerase I inhibitor. Topotecan induces cell cycle arrest in G0/G1 and S phases and promotes apoptosis. Topotecan shows anticancer activity.

At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form (Topotecan hydrochloride) usually boasts enhanced water solubility and stability.

For research use only. We do not sell to patients.

Topotecan Chemical Structure

Topotecan Chemical Structure

CAS No. : 123948-87-8

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Topotecan:

Other Forms of Topotecan:

Top Publications Citing Use of Products

    Topotecan purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761.  [Abstract]

    WDR5 inhibitor OICR-9429 enhances the sensitivity of ovarian cancer to genotoxic chemotherapeutics in vivo. Representative images and the apoptotic rate the indicated chemotherapy-treated xenograft tumors.

    Topotecan purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761.  [Abstract]

    IB analysis of the level of cleaved-caspase 3 and cleaved-PARP1 in the indicated chemotherapy-treated xenograft tumors. GAPDH served as the loading control.

    View All Topoisomerase Isoform Specific Products:

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Topotecan (SKF 104864A; NSC 609669) is an orally active and potent Topoisomerase I inhibitor. Topotecan induces cell cycle arrest in G0/G1 and S phases and promotes apoptosis. Topotecan shows anticancer activity[1].

    IC50 & Target[1]

    Topoisomerase I

     

    Cellular Effect
    Cell Line Type Value Description References
    2008 IC50
    > 500 nM
    Compound: 2
    Antiproliferative activity against human 2008 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human 2008 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    [PMID: 35932565]
    A2780 IC50
    0.006 μM
    Compound: 4
    Cytotoxicity against human A2780 cells overexpressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay
    Cytotoxicity against human A2780 cells overexpressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay
    [PMID: 22959246]
    A2780 IC50
    0.078 μM
    Compound: 2; TPT
    Antiproliferative activity against human A2780 cells after 96 hrs by MTT assay
    Antiproliferative activity against human A2780 cells after 96 hrs by MTT assay
    [PMID: 27871039]
    A2780 IC50
    1.1 μM
    Compound: Topotecan
    Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
    Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
    [PMID: 16792409]
    A2780 IC50
    1.2 μM
    Compound: Topotecan
    Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
    Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
    [PMID: 17125236]
    A2780 IC50
    22 μM
    Compound: Topotecan
    Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2
    Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2
    [PMID: 11063605]
    A2780 IC50
    22.6 μM
    Compound: Topotecan
    Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1
    Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1
    [PMID: 11063605]
    A2780 IC50
    3.35 μM
    Compound: 2, TPT
    Cytotoxicity against human A2780 cells after 4 days by MTT assay
    Cytotoxicity against human A2780 cells after 4 days by MTT assay
    [PMID: 18554906]
    A2780 IC50
    33 nM
    Compound: Topotecan
    Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
    Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
    [PMID: 24900725]
    A-375 IC50
    13 nM
    Compound: 7
    Cytotoxicity against human A375 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human A375 cells after 72 hrs by alamar blue assay
    [PMID: 21341674]
    A498 IC50
    2 μM
    Compound: Topotecan
    Inhibition of colony formation of human A498 cells after 2 weeks by crystal violet staining-based microscopic analysis
    Inhibition of colony formation of human A498 cells after 2 weeks by crystal violet staining-based microscopic analysis
    [PMID: 29993250]
    A549 IC50
    0.0032 μM
    Compound: topotecan
    Cytotoxicity against human A549 cells after 96 hrs by MTT assay
    Cytotoxicity against human A549 cells after 96 hrs by MTT assay
    [PMID: 15165144]
    A549 IC50
    0.005 μM
    Compound: topotecan, TPT
    Antitumor activity against human A549 cells after 4 hrs by MTT assay
    Antitumor activity against human A549 cells after 4 hrs by MTT assay
    [PMID: 18207748]
    A549 IC50
    0.007 μM
    Compound: 2; TPT
    Antiproliferative activity against human A549 cells after 96 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 96 hrs by MTT assay
    [PMID: 27871039]
    A549 IC50
    0.04 μM
    Compound: 2, Hycamtin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 20371183]
    A549 IC50
    0.045 μM
    Compound: 2
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    [PMID: 25438769]
    A549 IC50
    0.0452 μM
    Compound: 2
    Cytotoxicity against human A549 cells after 72 hrs sulforhodamine B colorimetric assay
    Cytotoxicity against human A549 cells after 72 hrs sulforhodamine B colorimetric assay
    [PMID: 25008456]
    A549 IC50
    0.071 μM
    Compound: 2, TPT
    Cytotoxicity against human A549 cells after 3 days
    Cytotoxicity against human A549 cells after 3 days
    [PMID: 21333532]
    A549 IC50
    0.11 μM
    Compound: 3; TPT
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    [PMID: 28789891]
    A549 IC50
    0.2 μM
    Compound: TPT
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 26725027]
    A549 IC50
    0.22 μM
    Compound: 2, TPT
    Cytotoxicity against human A549 cells after 4 days by MTT assay
    Cytotoxicity against human A549 cells after 4 days by MTT assay
    [PMID: 18554906]
    A549 IC50
    0.36 μM
    Compound: 3
    Antitumor activity against human A549/ATCC cells by SRB method
    Antitumor activity against human A549/ATCC cells by SRB method
    [PMID: 19541483]
    A549 IC50
    0.48 μM
    Compound: Topotecan
    Cytotoxicity against human A549 cells by SRB method
    Cytotoxicity against human A549 cells by SRB method
    [PMID: 18986807]
    A549 GI50
    0.9 μM
    Compound: 3, TPT
    Cytotoxicity against human A549 cells expressing wild type p53 after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells expressing wild type p53 after 48 hrs by SRB assay
    [PMID: 19715319]
    A549 IC50
    1.09 μM
    Compound: Topotecan
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    [PMID: 20202723]
    A549 IC50
    1.11 μM
    Compound: TPT
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    [PMID: 34990980]
    A549 IC50
    1.424 μM
    Compound: Topotecan
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 30227711]
    A549 IC50
    1.9 μM
    Compound: 3, TPT
    Cytotoxicity against human A549 cells expressing wild type p53 after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells expressing wild type p53 after 48 hrs by SRB assay
    [PMID: 19715319]
    A549 IC50
    112 nM
    Compound: 3
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    [PMID: 28927790]
    A549 IC50
    112 nM
    Compound: 3
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
    [PMID: 28285912]
    A549 IC50
    2.8 μM
    Compound: TPT
    Antiproliferative activity against human A549 cells after 3 days by MTT assay
    Antiproliferative activity against human A549 cells after 3 days by MTT assay
    [PMID: 23084702]
    A549 IC50
    24 nM
    Compound: Topotecan
    Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line
    Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line
    [PMID: 12408707]
    A549 IC50
    3.16 μM
    Compound: TPT, Hycamptin
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    [PMID: 21463912]
    A549 IC50
    3.3 μM
    Compound: Topotecan
    Cytotoxicity against human A549 cells after 96 hrs by MTT assay
    Cytotoxicity against human A549 cells after 96 hrs by MTT assay
    [PMID: 16792409]
    A549 IC50
    3.5 μM
    Compound: Topotecan
    Cytotoxicity against human A549 cells after 96 hrs by MTT assay
    Cytotoxicity against human A549 cells after 96 hrs by MTT assay
    [PMID: 17125236]
    A549 GI50
    3.96 μM
    Compound: TPT
    Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
    [PMID: 22867019]
    A549 IC50
    354 nM
    Compound: Topotecan
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 24900725]
    A549 IC50
    4.81 μM
    Compound: Topotecan
    Antiproliferative activity against human A549 cells after 3 days by XTT assay
    Antiproliferative activity against human A549 cells after 3 days by XTT assay
    [PMID: 24727241]
    A549 IC50
    4.81 μM
    Compound: Top
    Antiproliferative activity against human A549 cells after 72 hrs by XTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by XTT assay
    [PMID: 23237975]
    A549 GI50
    5.98 μM
    Compound: Topotecan
    Growth inhibition of human A549 cells after 72 hrs by XTT assay
    Growth inhibition of human A549 cells after 72 hrs by XTT assay
    [PMID: 22079254]
    A549 GI50
    5.98 μM
    Compound: Topotecan
    Antiproliferative activity against human A549 cells after 72 hrs by XTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by XTT assay
    [PMID: 19796956]
    A549 IC50
    58.4 nM
    Compound: Topotecan
    Cytotoxicity against human A549 cells assessed as growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition measured after 72 hrs by MTT assay
    [PMID: 31881457]
    A549 IC50
    7.4 μM
    Compound: TPT
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 26226379]
    A549 IC50
    8.3 μM
    Compound: Topotecan
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay
    [PMID: 35238576]
    AGS GI50
    0.1 μM
    Compound: 3, TPT
    Cytotoxicity against human AGS cells expressing wild type p53 after 48 hrs by SRB assay
    Cytotoxicity against human AGS cells expressing wild type p53 after 48 hrs by SRB assay
    [PMID: 19715319]
    AGS IC50
    0.3 μM
    Compound: 3, TPT
    Cytotoxicity against human AGS cells expressing wild type p53 after 48 hrs by SRB assay
    Cytotoxicity against human AGS cells expressing wild type p53 after 48 hrs by SRB assay
    [PMID: 19715319]
    Astrocyte IC50
    0.16 μM
    Compound: Topotecan
    Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method
    Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method
    [PMID: 26355532]
    Bel-7402 IC50
    0.0012 μM
    Compound: topotecan
    Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay
    [PMID: 15165144]
    Bel-7402 IC50
    0.1 μM
    Compound: 2; TPT
    Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay
    Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay
    [PMID: 27871039]
    Bel-7402 IC50
    0.47 μM
    Compound: 2, TPT
    Cytotoxicity against human Bel7402 cells after 3 days
    Cytotoxicity against human Bel7402 cells after 3 days
    [PMID: 21333532]
    Bel-7402 IC50
    1.2 μM
    Compound: Topotecan
    Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay
    [PMID: 16792409]
    Bel-7402 IC50
    1.4 μM
    Compound: Topotecan
    Cytotoxicity against human Bel-7402 cells after 96 hrs by MTT assay
    Cytotoxicity against human Bel-7402 cells after 96 hrs by MTT assay
    [PMID: 17125236]
    Bel-7402 IC50
    3.13 μM
    Compound: 2, TPT
    Cytotoxicity against human BEL-7402 cells after 4 days by MTT assay
    Cytotoxicity against human BEL-7402 cells after 4 days by MTT assay
    [PMID: 18554906]
    Bel-7402 IC50
    7.118 μM
    Compound: Topotecan
    Cytotoxicity in human Bel7402 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human Bel7402 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 30227711]
    BGC-823 IC50
    0.0043 μM
    Compound: topotecan
    Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay
    [PMID: 15165144]
    BGC-823 IC50
    0.078 μM
    Compound: 2; TPT
    Antiproliferative activity against human BGC823 cells after 96 hrs by MTT assay
    Antiproliferative activity against human BGC823 cells after 96 hrs by MTT assay
    [PMID: 27871039]
    BGC-823 IC50
    3.8 μM
    Compound: Topotecan
    Cytotoxicity against human BGC-823 cells after 96 hrs by MTT assay
    Cytotoxicity against human BGC-823 cells after 96 hrs by MTT assay
    [PMID: 17125236]
    BGC-823 IC50
    4.4 μM
    Compound: Topotecan
    Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay
    [PMID: 16792409]
    Bone marrow cell IC50
    130 nM
    Compound: 7
    Cytotoxicity against human bone marrow cell by CFU-GM assay
    Cytotoxicity against human bone marrow cell by CFU-GM assay
    [PMID: 21341674]
    Bone marrow cell IC50
    8 nM
    Compound: 7
    Cytotoxicity against mouse bone marrow cell by CFU-GM assay
    Cytotoxicity against mouse bone marrow cell by CFU-GM assay
    [PMID: 21341674]
    BXPC-3 IC50
    0.62 μM
    Compound: 2, TPT
    Cytotoxicity against human BXPC3 cells after 4 days by MTT assay
    Cytotoxicity against human BXPC3 cells after 4 days by MTT assay
    [PMID: 18554906]
    C6 IC50
    5.8 μM
    Compound: Topotecan
    Antiproliferative activity against rat C6 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Antiproliferative activity against rat C6 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    [PMID: 34537445]
    COR-L23 IC50
    13.2 nM
    Compound: Topotecan
    Cytotoxicity measured using the COR-L23 parental (COR-L23/P) human non small cell lung carcinoma cell line
    Cytotoxicity measured using the COR-L23 parental (COR-L23/P) human non small cell lung carcinoma cell line
    [PMID: 11806724]
    DU-145 GI50
    0.01 μM
    Compound: 2
    Growth inhibition of human DU145 cells by five-dose growth inhibition assay
    Growth inhibition of human DU145 cells by five-dose growth inhibition assay
    [PMID: 25909279]
    DU-145 IC50
    1.2 μM
    Compound: Topotecan
    Antiproliferative activity against human DU145 cells by [3H]thymidine incorporation assay
    Antiproliferative activity against human DU145 cells by [3H]thymidine incorporation assay
    [PMID: 20932758]
    DU-145 IC50
    1000 nM
    Compound: 7
    Cytotoxicity against human DU145 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human DU145 cells after 72 hrs by alamar blue assay
    [PMID: 21341674]
    GES1 IC50
    6.22 μM
    Compound: TPT
    Antiproliferative activity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    [PMID: 34990980]
    GES1 IC50
    8.55 μM
    Compound: TPT
    Antiproliferative activity against human GES1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human GES1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    [PMID: 34774339]
    H69AR IC50
    > 300 nM
    Compound: 7
    Cytotoxicity against human H69AR cells overexpressing MDR1 after 72 hrs by alamar blue assay
    Cytotoxicity against human H69AR cells overexpressing MDR1 after 72 hrs by alamar blue assay
    [PMID: 21341674]
    HCT-116 GI50
    0.03 μM
    Compound: 2
    Growth inhibition of human HCT116 cells by five-dose growth inhibition assay
    Growth inhibition of human HCT116 cells by five-dose growth inhibition assay
    [PMID: 25909279]
    HCT-116 IC50
    0.0889 μM
    Compound: TPT
    Antiproliferative activity against human HCT116 cells after 3 days by MTT assay
    Antiproliferative activity against human HCT116 cells after 3 days by MTT assay
    [PMID: 23084702]
    HCT-116 GI50
    0.4 μM
    Compound: TPT
    Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTT assay
    [PMID: 22867019]
    HCT-116 IC50
    0.7 μM
    Compound: TPT
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 26226379]
    HCT-116 IC50
    0.97 μM
    Compound: Topotecan
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay
    [PMID: 35238576]
    HCT-116 IC50
    1.1 μM
    Compound: TPT, Hycamptin
    Cytotoxicity against human HCT116 cells after 3 days by MTT assay
    Cytotoxicity against human HCT116 cells after 3 days by MTT assay
    [PMID: 21463912]
    HCT-116 IC50
    4.32 μM
    Compound: TPT
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 24826818]
    HCT-116 IC50
    70.35 μM
    Compound: TPT
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    [PMID: 26725027]
    HCT-8 IC50
    0.0015 μM
    Compound: topotecan
    Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
    [PMID: 15165144]
    HCT-8 IC50
    0.022 μM
    Compound: 2; TPT
    Antiproliferative activity against human HCT8 cells after 96 hrs by MTT assay
    Antiproliferative activity against human HCT8 cells after 96 hrs by MTT assay
    [PMID: 27871039]
    HCT-8 IC50
    0.07 μM
    Compound: Topotecan
    Cytotoxicity against human HCT8 cells after 3 days by MTT assay
    Cytotoxicity against human HCT8 cells after 3 days by MTT assay
    [PMID: 20392545]
    HCT-8 IC50
    1.2 μM
    Compound: Topotecan
    Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
    [PMID: 17125236]
    HCT-8 IC50
    1.5 μM
    Compound: Topotecan
    Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
    [PMID: 16792409]
    HCT-8 IC50
    3.66 μM
    Compound: 2, TPT
    Cytotoxicity against human HCT8 cells by MTT assay
    Cytotoxicity against human HCT8 cells by MTT assay
    [PMID: 19056266]
    HEK293 IC50
    1.3 μM
    Compound: topotecan
    Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
    Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
    [PMID: 23241029]
    HEK293 IC50
    61 μM
    Compound: topotecan
    Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay
    Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay
    [PMID: 23241029]
    HEK293 IC50
    8.6 μM
    Compound: topotecan
    Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
    Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
    [PMID: 23241029]
    HEL IC50
    26 μM
    Compound: Topotecan
    Antiproliferative activity against HEL cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay
    Antiproliferative activity against HEL cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay
    [PMID: 35238576]
    HeLa GI50
    0.03 μM
    Compound: topotecan
    Growth inhibition of HeLa cells after 4 days
    Growth inhibition of HeLa cells after 4 days
    [PMID: 17418582]
    HeLa GI50
    0.08 μM
    Compound: 3, TPT
    Cytotoxicity against p53-deficient human HeLa cells after 48 hrs by SRB assay
    Cytotoxicity against p53-deficient human HeLa cells after 48 hrs by SRB assay
    [PMID: 19715319]
    HeLa IC50
    0.73 μM
    Compound: Topotecan
    Inhibition of DNA topoisomerase 2 in human HeLa cells incubated for 18 to 24 hrs by kinase assay
    Inhibition of DNA topoisomerase 2 in human HeLa cells incubated for 18 to 24 hrs by kinase assay
    [PMID: 31416740]
    HeLa IC50
    1.6 μM
    Compound: 3, TPT
    Cytotoxicity against p53-deficient human HeLa cells after 48 hrs by SRB assay
    Cytotoxicity against p53-deficient human HeLa cells after 48 hrs by SRB assay
    [PMID: 19715319]
    HeLa IC50
    376 nM
    Compound: Topotecan
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 24900725]
    HeLa CC50
    4.5 μM
    Compound: Tpc
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 3 days by fluorometric assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 3 days by fluorometric assay
    [PMID: 32786885]
    Hep 3B2 GI50
    0.22 μM
    Compound: Topotecan
    Growth inhibition of human Hep3B cells after 72 hrs by XTT assay
    Growth inhibition of human Hep3B cells after 72 hrs by XTT assay
    [PMID: 22079254]
    Hep 3B2 GI50
    0.22 μM
    Compound: Topotecan
    Antiproliferative activity against human Hep3B cells after 72 hrs by XTT assay
    Antiproliferative activity against human Hep3B cells after 72 hrs by XTT assay
    [PMID: 19796956]
    Hep 3B2 GI50
    0.4 μM
    Compound: 3, TPT
    Cytotoxicity against p53-deficient human Hep3B cells after 48 hrs by SRB assay
    Cytotoxicity against p53-deficient human Hep3B cells after 48 hrs by SRB assay
    [PMID: 19715319]
    Hep 3B2 IC50
    1.4 μM
    Compound: 3, TPT
    Cytotoxicity against p53-deficient human Hep3B cells after 48 hrs by SRB assay
    Cytotoxicity against p53-deficient human Hep3B cells after 48 hrs by SRB assay
    [PMID: 19715319]
    Hep 3B2 IC50
    7.9 nM
    Compound: Topotecan
    Cytotoxicity against human Hep3B cells assessed as growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human Hep3B cells assessed as growth inhibition measured after 72 hrs by MTT assay
    [PMID: 31881457]
    HepG2 IC50
    0.06 μM
    Compound: 2, TPT
    Cytotoxicity against human HepG2 cells after 4 days by MTT assay
    Cytotoxicity against human HepG2 cells after 4 days by MTT assay
    [PMID: 18554906]
    HepG2 IC50
    0.237 μM
    Compound: Topotecan
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 30227711]
    HepG2 GI50
    1.2 μM
    Compound: 3, TPT
    Cytotoxicity against human HepG2 cells expressing wild type p53 after 48 hrs by SRB assay
    Cytotoxicity against human HepG2 cells expressing wild type p53 after 48 hrs by SRB assay
    [PMID: 19715319]
    HepG2 IC50
    1.6 μM
    Compound: 3, TPT
    Cytotoxicity against human HepG2 cells expressing wild type p53 after 48 hrs by SRB assay
    Cytotoxicity against human HepG2 cells expressing wild type p53 after 48 hrs by SRB assay
    [PMID: 19715319]
    HepG2 IC50
    1.66 μM
    Compound: TPT
    Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 24826818]
    HepG2 IC50
    2.55 μM
    Compound: TPT
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 26725027]
    HepG2 IC50
    3.28 μM
    Compound: TPT
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    [PMID: 34990980]
    HepG2 IC50
    3.3 μM
    Compound: Topotecan
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay
    [PMID: 35238576]
    HepG2 GI50
    3.83 μM
    Compound: Topotecan
    Growth inhibition of human HepG2 cells after 72 hrs by XTT assay
    Growth inhibition of human HepG2 cells after 72 hrs by XTT assay
    [PMID: 22079254]
    HepG2 GI50
    3.83 μM
    Compound: Topotecan
    Antiproliferative activity against human HepG2 cells after 72 hrs by XTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by XTT assay
    [PMID: 19796956]
    HGC-27 IC50
    0.22 μM
    Compound: TPT
    Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    [PMID: 34990980]
    HGC-27 IC50
    10.82 μM
    Compound: TPT
    Antiproliferative activity against human HGC-27 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human HGC-27 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    [PMID: 34774339]
    HL-60 IC50
    0.012 μM
    Compound: 3
    Antitumor activity against human HL60 cells by SRB method
    Antitumor activity against human HL60 cells by SRB method
    [PMID: 19541483]
    HL-60 IC50
    0.052 μM
    Compound: 2, TPT
    Cytotoxicity against human HL60 cells after 3 days
    Cytotoxicity against human HL60 cells after 3 days
    [PMID: 21333532]
    HL-60 IC50
    1 μM
    Compound: 5al
    Inhibition of Topoisomerase I by cleavage complex formation in human HL-60 cells
    Inhibition of Topoisomerase I by cleavage complex formation in human HL-60 cells
    [PMID: 8410981]
    HMLE IC50
    0.75 μM
    Compound: TPT
    Antiproliferative activity against human HMLE cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human HMLE cells assessed as reduction in cell viability by MTT assay
    [PMID: 28197320]
    HOP-62 GI50
    0.01 μM
    Compound: 2
    Growth inhibition of human HOP62 cells by five-dose growth inhibition assay
    Growth inhibition of human HOP62 cells by five-dose growth inhibition assay
    [PMID: 25909279]
    HT-1080 IC50
    0.18 μM
    Compound: Topotecan
    Antiproliferative activity against human HT1080 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HT1080 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B assay
    [PMID: 26408815]
    HT-1080 IC50
    0.5 μM
    Compound: Tpt
    Antiproliferative activity against human HT1080 cells after 48 hrs by SRB assay
    Antiproliferative activity against human HT1080 cells after 48 hrs by SRB assay
    [PMID: 29936355]
    HT-29 IC50
    > 1000 nM
    Compound: 7
    Cytotoxicity against human HT-29 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human HT-29 cells after 72 hrs by alamar blue assay
    [PMID: 21341674]
    HT-29 GI50
    0.08 μM
    Compound: 3, TPT
    Cytotoxicity against human HT-29 cells expressing p53 mutant after 48 hrs by SRB assay
    Cytotoxicity against human HT-29 cells expressing p53 mutant after 48 hrs by SRB assay
    [PMID: 19715319]
    HT-29 IC50
    0.23 μM
    Compound: Topotecan
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B assay
    [PMID: 26408815]
    HT-29 IC50
    0.375 μM
    Compound: Topotecan
    Cytotoxicity against human HT-29 cells by SRB method
    Cytotoxicity against human HT-29 cells by SRB method
    [PMID: 18986807]
    HT-29 IC50
    0.4 μM
    Compound: 3, TPT
    Cytotoxicity against human HT-29 cells expressing p53 mutant after 48 hrs by SRB assay
    Cytotoxicity against human HT-29 cells expressing p53 mutant after 48 hrs by SRB assay
    [PMID: 19715319]
    HT-29 IC50
    0.41 μM
    Compound: Tpt
    Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay
    Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay
    [PMID: 29936355]
    HT-29 IC50
    0.41 μM
    Compound: 3
    Antitumor activity against human HT-29 cells by SRB method
    Antitumor activity against human HT-29 cells by SRB method
    [PMID: 19541483]
    HT-29 IC50
    0.88 μM
    Compound: 2, TPT
    Cytotoxicity against human HT29 cells after 4 days by MTT assay
    Cytotoxicity against human HT29 cells after 4 days by MTT assay
    [PMID: 18554906]
    HT-29 IC50
    1.35 μM
    Compound: topotecan
    Antiproliferative activity against human HT29 cells after 1 hr of drug exposure measured after 72 hrs
    Antiproliferative activity against human HT29 cells after 1 hr of drug exposure measured after 72 hrs
    [PMID: 18424133]
    HT-29 IC50
    25 nM
    Compound: 3
    Human tumor cell cytotoxicity assay was performed using MTT (HT-29 cell line )
    Human tumor cell cytotoxicity assay was performed using MTT (HT-29 cell line )
    [PMID: 8576914]
    HT-29 IC50
    25 nM
    Compound: Topotecan
    Cytotoxicity was determined in vitro in HT-29 cells(colon) of human tumor cell lines by using MTT assay
    Cytotoxicity was determined in vitro in HT-29 cells(colon) of human tumor cell lines by using MTT assay
    [PMID: 7853331]
    HT-29 IC50
    3.28 μM
    Compound: TPT
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    [PMID: 34990980]
    HT-29 IC50
    46.29 μM
    Compound: topotecan
    Antiproliferative activity against BCRP overexpressing mitoxantrone-resistant human HT29 cells after 1 hr of drug exposure measured after 72 hrs
    Antiproliferative activity against BCRP overexpressing mitoxantrone-resistant human HT29 cells after 1 hr of drug exposure measured after 72 hrs
    [PMID: 18424133]
    Huh-7 IC50
    8.61 μM
    Compound: Topotecan
    Antiproliferative activity against human HuH7 cells after 3 days by XTT assay
    Antiproliferative activity against human HuH7 cells after 3 days by XTT assay
    [PMID: 24727241]
    Huh-7 IC50
    8.61 μM
    Compound: Topotecan
    Antiproliferative activity against human HuH7 cells after 72 hrs by XTT assay
    Antiproliferative activity against human HuH7 cells after 72 hrs by XTT assay
    [PMID: 26686931]
    IGROV-1 IC50
    160 nM
    Compound: 7
    Cytotoxicity against human IGROV1 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human IGROV1 cells after 72 hrs by alamar blue assay
    [PMID: 21341674]
    K562 IC50
    0.91 μM
    Compound: Topotecan
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay
    [PMID: 35238576]
    K562 IC50
    1.15 μM
    Compound: TPT
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability by MTT assay
    [PMID: 28197320]
    K562 IC50
    1.7 μM
    Compound: 3, TPT
    Cytotoxicity against p53-deficient human K562 cells after 48 hrs by SRB assay
    Cytotoxicity against p53-deficient human K562 cells after 48 hrs by SRB assay
    [PMID: 19715319]
    K562 IC50
    500 nM
    Compound: Topotecan
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    [PMID: 24900725]
    KB IC50
    > 200 μM
    Compound: TPT
    Antiproliferative activity against human KB cells assessed as growth inhibition after 48 hrs by MTT assay
    Antiproliferative activity against human KB cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 24826818]
    KB IC50
    0.0625 μM
    Compound: 2
    Cytotoxicity against human KB cells after 72 hrs sulforhodamine B colorimetric assay
    Cytotoxicity against human KB cells after 72 hrs sulforhodamine B colorimetric assay
    [PMID: 25008456]
    KB IC50
    0.063 μM
    Compound: 2
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    [PMID: 25438769]
    KB IC50
    0.07 μM
    Compound: Topotecan
    Cytotoxicity against human KB cells after 3 days by MTT assay
    Cytotoxicity against human KB cells after 3 days by MTT assay
    [PMID: 20392545]
    KB IC50
    0.101 μM
    Compound: 3; TPT
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    [PMID: 28789891]
    KB IC50
    0.22 μM
    Compound: 2, TPT
    Cytotoxicity against human KB cells after 4 days by MTT assay
    Cytotoxicity against human KB cells after 4 days by MTT assay
    [PMID: 18554906]
    KB IC50
    102 nM
    Compound: 3
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    [PMID: 28927790]
    KB IC50
    102 nM
    Compound: 3
    Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
    [PMID: 28285912]
    KB IC50
    2.61 μM
    Compound: Topotecan
    Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 30227711]
    KB IC50
    71.8 nM
    Compound: Topotecan
    Cytotoxicity against human KB cells assessed as growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human KB cells assessed as growth inhibition measured after 72 hrs by MTT assay
    [PMID: 31881457]
    KB 3-1 IC50
    0.04 μM
    Compound: Topotecan
    Cytotoxicity against human KB3-1 cells after MTT assay
    Cytotoxicity against human KB3-1 cells after MTT assay
    [PMID: 18829334]
    KB 3-1 IC50
    0.04 μM
    Compound: TPT
    Cytotoxicity against human KB3-1 cells after 4 days by MTT method
    Cytotoxicity against human KB3-1 cells after 4 days by MTT method
    [PMID: 19303306]
    KB 3-1 IC50
    0.04 μM
    Compound: Topotecan
    Cytotoxicity against human KB3-1 cells by MTT method
    Cytotoxicity against human KB3-1 cells by MTT method
    [PMID: 19012996]
    KB 3-1 IC50
    0.04 μM
    Compound: topotecan
    Cytotoxicity against human KB3-1 cells by MTT method
    Cytotoxicity against human KB3-1 cells by MTT method
    [PMID: 18771930]
    KB-V1 IC50
    0.44 μM
    Compound: Topotecan
    Cytotoxicity against multidrug resistant human KBV-1 cells overexpressing MDR1 after MTT assay
    Cytotoxicity against multidrug resistant human KBV-1 cells overexpressing MDR1 after MTT assay
    [PMID: 18829334]
    KB-V1 IC50
    0.44 μM
    Compound: TPT
    Cytotoxicity against MDR1 overexpressing human KBV1 cells after 4 days by MTT method
    Cytotoxicity against MDR1 overexpressing human KBV1 cells after 4 days by MTT method
    [PMID: 19303306]
    KB-V1 IC50
    0.44 μM
    Compound: Topotecan
    Cytotoxicity against multidrug resistant human KBV1 cells overexpressing MDR1 by MTT method
    Cytotoxicity against multidrug resistant human KBV1 cells overexpressing MDR1 by MTT method
    [PMID: 19012996]
    KB-V1 IC50
    0.44 μM
    Compound: topotecan
    Cytotoxicity against human KBV1 cells by MTT method
    Cytotoxicity against human KBV1 cells by MTT method
    [PMID: 18771930]
    KETR3 IC50
    0.0049 μM
    Compound: topotecan
    Cytotoxicity against human Ketr3 cells after 96 hrs by MTT assay
    Cytotoxicity against human Ketr3 cells after 96 hrs by MTT assay
    [PMID: 15165144]
    LNCaP IC50
    9 nM
    Compound: 7
    Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay
    Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay
    [PMID: 21341674]
    LoVo IC50
    0.02 μM
    Compound: 2, Hycamtin
    Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
    Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
    [PMID: 20371183]
    LoVo IC50
    0.036 μM
    Compound: topotecan, TPT
    Antitumor activity against human LOVO cells after 4 hrs by MTT assay
    Antitumor activity against human LOVO cells after 4 hrs by MTT assay
    [PMID: 18207748]
    LoVo IC50
    1.21 μM
    Compound: Topotecan
    Cytotoxicity against human LoVo cells after 3 days by MTT assay
    Cytotoxicity against human LoVo cells after 3 days by MTT assay
    [PMID: 20202723]
    LoVo IC50
    11.6 nM
    Compound: Topotecan
    Cytotoxic potentiation of Topotecan (TP) by the compound in (human colorectal cancer LoVo cell line
    Cytotoxic potentiation of Topotecan (TP) by the compound in (human colorectal cancer LoVo cell line
    [PMID: 12408707]
    LOX IMVI IC50
    5 nM
    Compound: Topotecan
    Cytotoxicity was determined in vitro in LOX cells (melanoma) of human tumor cell lines by using MTT assay
    Cytotoxicity was determined in vitro in LOX cells (melanoma) of human tumor cell lines by using MTT assay
    [PMID: 7853331]
    M21 IC50
    1.4 μM
    Compound: Tpt
    Antiproliferative activity against human M21 cells after 48 hrs by SRB assay
    Antiproliferative activity against human M21 cells after 48 hrs by SRB assay
    [PMID: 29936355]
    M21 IC50
    1.4 μM
    Compound: Topotecan
    Antiproliferative activity against human M21 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human M21 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B assay
    [PMID: 26408815]
    Malme-3M IC50
    1000 nM
    Compound: 7
    Cytotoxicity against human MALME-3M cells after 72 hrs by alamar blue assay
    Cytotoxicity against human MALME-3M cells after 72 hrs by alamar blue assay
    [PMID: 21341674]
    MCF7 GI50
    > 10 μM
    Compound: Topotecan
    Growth inhibition of human MCF7 cells after 72 hrs by XTT assay
    Growth inhibition of human MCF7 cells after 72 hrs by XTT assay
    [PMID: 22079254]
    MCF7 IC50
    0.0018 μM
    Compound: topotecan
    Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
    [PMID: 15165144]
    MCF7 GI50
    0.01 μM
    Compound: 2
    Growth inhibition of human MCF7 cells by five-dose growth inhibition assay
    Growth inhibition of human MCF7 cells by five-dose growth inhibition assay
    [PMID: 25909279]
    MCF7 IC50
    0.024 μM
    Compound: Topotecan
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B assay
    [PMID: 26408815]
    MCF7 GI50
    0.04 μM
    Compound: topotecan
    Growth inhibition of adriamycin-resistant MCF7 cells after 4 days
    Growth inhibition of adriamycin-resistant MCF7 cells after 4 days
    [PMID: 17418582]
    MCF7 GI50
    0.05 μM
    Compound: topotecan
    Growth inhibition of MCF7 cells after 4 days
    Growth inhibition of MCF7 cells after 4 days
    [PMID: 17418582]
    MCF7 IC50
    0.14 μM
    Compound: Topotecan
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay
    [PMID: 35238576]
    MCF7 IC50
    0.15 μM
    Compound: Topotecan
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    [PMID: 20392545]
    MCF7 IC50
    0.2 μM
    Compound: Tpt
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    [PMID: 29936355]
    MCF7 IC50
    0.26 μM
    Compound: TPT
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    [PMID: 34990980]
    MCF7 IC50
    0.28 μM
    Compound: 3; TPT
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    [PMID: 28789891]
    MCF7 GI50
    0.35 μM
    Compound: TPT
    Cytotoxicity against human MCF-7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MCF-7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    [PMID: 34008967]
    MCF7 IC50
    0.48 μM
    Compound: Topotecan
    Inhibition of DNA topoisomerase 2 in human MCF7 cells incubated for 18 to 24 hrs by kinase assay
    Inhibition of DNA topoisomerase 2 in human MCF7 cells incubated for 18 to 24 hrs by kinase assay
    [PMID: 31416740]
    MCF7 IC50
    0.488 μM
    Compound: topotecan, TPT
    Antitumor activity against human MCF7 cells after 4 hrs by MTT assay
    Antitumor activity against human MCF7 cells after 4 hrs by MTT assay
    [PMID: 18207748]
    MCF7 GI50
    0.8 μM
    Compound: 3, TPT
    Cytotoxicity against estrogen receptor-positive human MCF7 cells expressing wild type p53 after 48 hrs by SRB assay
    Cytotoxicity against estrogen receptor-positive human MCF7 cells expressing wild type p53 after 48 hrs by SRB assay
    [PMID: 19715319]
    MCF7 IC50
    1.2 μM
    Compound: 2, TPT
    Cytotoxicity against human MCF7 cells after 4 days by MTT assay
    Cytotoxicity against human MCF7 cells after 4 days by MTT assay
    [PMID: 18554906]
    MCF7 IC50
    1.8 μM
    Compound: Topotecan
    Poison activity at TOP1 in human MCF7 cells assessed as decrease in relaxed supercoiled pBS(SK+) DNA mobility measured after 30 mins by ethidium bromide staining based agarose gel electrophoresis
    Poison activity at TOP1 in human MCF7 cells assessed as decrease in relaxed supercoiled pBS(SK+) DNA mobility measured after 30 mins by ethidium bromide staining based agarose gel electrophoresis
    [PMID: 30897325]
    MCF7 IC50
    1.9 μM
    Compound: Topotecan
    Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
    [PMID: 16792409]
    MCF7 IC50
    14.3 μM
    Compound: TPT
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 24826818]
    MCF7 IC50
    2 μM
    Compound: 3, TPT
    Cytotoxicity against estrogen receptor-positive human MCF7 cells expressing wild type p53 after 48 hrs by SRB assay
    Cytotoxicity against estrogen receptor-positive human MCF7 cells expressing wild type p53 after 48 hrs by SRB assay
    [PMID: 19715319]
    MCF7 IC50
    2.135 μM
    Compound: Topotecan
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 30227711]
    MCF7 GI50
    2.59 μM
    Compound: TPT
    Cytotoxicity against human MCF-7/TDP1 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MCF-7/TDP1 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    [PMID: 34008967]
    MCF7 IC50
    3.46 μM
    Compound: Topotecan
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    [PMID: 25147141]
    MCF7 IC50
    34.5 nM
    Compound: Topotecan
    Cytotoxicity against human MCF7 cells assessed as growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition measured after 72 hrs by MTT assay
    [PMID: 31881457]
    MCF7 IC50
    5.55 μM
    Compound: 2, TPT
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    [PMID: 19056266]
    MCF7 IC50
    5.97 μM
    Compound: Topotecan
    Antiproliferative activity against human MCF7 cells after 3 days by XTT assay
    Antiproliferative activity against human MCF7 cells after 3 days by XTT assay
    [PMID: 24727241]
    MCF7 IC50
    5.97 μM
    Compound: Top
    Antiproliferative activity against human MCF7 cells after 72 hrs by XTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by XTT assay
    [PMID: 23237975]
    MCF7 IC50
    63 nM
    Compound: Topotecan
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    [PMID: 24900725]
    MCF7 IC50
    666 nM
    Compound: 3
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    [PMID: 28927790]
    MCF7 IC50
    666 nM
    Compound: 3
    Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    [PMID: 28285912]
    MDA-MB-231 IC50
    < 0.1 μM
    Compound: Topotecan
    Antiproliferative activity against human MDA-MB-231 cells after 3 days by XTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 3 days by XTT assay
    [PMID: 24727241]
    MDA-MB-231 IC50
    < 0.1 μM
    Compound: Topotecan
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by XTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by XTT assay
    [PMID: 26686931]
    MDA-MB-231 IC50
    < 0.1 μM
    Compound: Top
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by XTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by XTT assay
    [PMID: 23237975]
    MDA-MB-231 IC50
    > 500 nM
    Compound: Topotecan
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    [PMID: 24900725]
    MDA-MB-231 GI50
    0.078 μM
    Compound: Topotecan
    Growth inhibition of human MDA-MB-231 cells after 72 hrs by XTT assay
    Growth inhibition of human MDA-MB-231 cells after 72 hrs by XTT assay
    [PMID: 22079254]
    MDA-MB-231 IC50
    0.1 μM
    Compound: 2
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay
    [PMID: 25438769]
    MDA-MB-231 IC50
    0.102 μM
    Compound: 2
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs sulforhodamine B colorimetric assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs sulforhodamine B colorimetric assay
    [PMID: 25008456]
    MDA-MB-231 IC50
    0.77 μM
    Compound: 3; TPT
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay
    [PMID: 28789891]
    MDA-MB-231 IC50
    1.898 μM
    Compound: Topotecan
    Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 30227711]
    MDA-MB-231 IC50
    101.5 nM
    Compound: Topotecan
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition measured after 72 hrs by MTT assay
    [PMID: 31881457]
    MDA-MB-231 IC50
    773 nM
    Compound: 3
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay
    [PMID: 28927790]
    MDA-MB-231 IC50
    773 nM
    Compound: 3
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay
    [PMID: 28285912]
    MDA-MB-435 IC50
    < 0.001 μM
    Compound: 2, Hycamtin
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    [PMID: 20371183]
    MDA-MB-435 GI50
    0.034 μM
    Compound: TPT
    Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by MTT assay
    [PMID: 22867019]
    MDA-MB-435 IC50
    0.079 μM
    Compound: Topotecan
    Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay
    Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay
    [PMID: 20202723]
    MDA-MB-435 IC50
    0.4 μM
    Compound: TPT
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    [PMID: 26226379]
    MDA-MB-435 IC50
    0.448 μM
    Compound: TPT, Hycamptin
    Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay
    Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay
    [PMID: 21463912]
    MDA-MB-435 IC50
    0.917 μM
    Compound: TPT
    Antiproliferative activity against human MDA-MB-435 cells after 3 days by MTT assay
    Antiproliferative activity against human MDA-MB-435 cells after 3 days by MTT assay
    [PMID: 23084702]
    MES-SA IC50
    4 nM
    Compound: 7
    Cytotoxicity against human MESSA cells after 72 hrs by alamar blue assay
    Cytotoxicity against human MESSA cells after 72 hrs by alamar blue assay
    [PMID: 21341674]
    MES-SA/Dx5 IC50
    33 nM
    Compound: 7
    Cytotoxicity against human MES-SA/Dx5 cells overexpressing MDR1 after 72 hrs by alamar blue assay
    Cytotoxicity against human MES-SA/Dx5 cells overexpressing MDR1 after 72 hrs by alamar blue assay
    [PMID: 21341674]
    MGC-803 IC50
    0.19 μM
    Compound: Topotecan
    Cytotoxicity in human MGC803 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human MGC803 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 30227711]
    MGC-803 IC50
    0.74 μM
    Compound: TPT
    Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    [PMID: 34774339]
    MOLT-4 IC50
    19 nM
    Compound: Topotecan
    Cytotoxicity against human MOLT4 cells after 72 hrs by MTT assay
    Cytotoxicity against human MOLT4 cells after 72 hrs by MTT assay
    [PMID: 24900725]
    MRC5 IC50
    4.25 μM
    Compound: Topotecan
    Antiproliferative activity against human MRC5 cells after 72 hrs by XTT assay
    Antiproliferative activity against human MRC5 cells after 72 hrs by XTT assay
    [PMID: 26686931]
    MRC5 GI50
    4.25 μM
    Compound: Topotecan
    Cytotoxicity against human MRC5 cells after 72 hrs by XTT assay
    Cytotoxicity against human MRC5 cells after 72 hrs by XTT assay
    [PMID: 19796956]
    NCI-H1299 GI50
    > 10 μM
    Compound: Topotecan
    Growth inhibition of human H1299 cells after 72 hrs by XTT assay
    Growth inhibition of human H1299 cells after 72 hrs by XTT assay
    [PMID: 22079254]
    NCI-H1299 GI50
    > 10 μM
    Compound: Topotecan
    Antiproliferative activity against human H1299 cells after 72 hrs by XTT assay
    Antiproliferative activity against human H1299 cells after 72 hrs by XTT assay
    [PMID: 19796956]
    NCI-H1299 IC50
    10.97 μM
    Compound: TPT
    Antiproliferative activity against human NCI-H1299 cells assessed as growth inhibition after 48 hrs by MTT assay
    Antiproliferative activity against human NCI-H1299 cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 24826818]
    NCI-H1299 IC50
    4.18 μM
    Compound: Topotecan
    Antiproliferative activity against human H1299 cells after 24 hrs by MTT assay
    Antiproliferative activity against human H1299 cells after 24 hrs by MTT assay
    [PMID: 25147141]
    NCI-H1299 IC50
    6.02 μM
    Compound: Topotecan
    Antiproliferative activity against human H1299 cells after 3 days by XTT assay
    Antiproliferative activity against human H1299 cells after 3 days by XTT assay
    [PMID: 24727241]
    NCI-H1299 IC50
    6.02 μM
    Compound: Topotecan
    Antiproliferative activity against human H1299 cells after 72 hrs by XTT assay
    Antiproliferative activity against human H1299 cells after 72 hrs by XTT assay
    [PMID: 26686931]
    NCI-H1299 IC50
    6.02 μM
    Compound: Top
    Antiproliferative activity against human H1299 cells after 72 hrs by XTT assay
    Antiproliferative activity against human H1299 cells after 72 hrs by XTT assay
    [PMID: 23237975]
    NCI-H460 GI50
    > 1000 nM
    Compound: 20
    Cytotoxicity against human mitoxantrone-resistant H460 cells after 72 hrs by MTT assay
    Cytotoxicity against human mitoxantrone-resistant H460 cells after 72 hrs by MTT assay
    [PMID: 24502276]
    NCI-H460 IC50
    0.008 μg/mL
    Compound: topotecan
    Antiproliferative activity against human NCI-H460 cells after 72 hrs
    Antiproliferative activity against human NCI-H460 cells after 72 hrs
    [PMID: 17190463]
    NCI-H460 IC50
    0.016 μM
    Compound: Topotecan
    Antiproliferative activity against human NCI-H460 cells after 72 hrs by coulter counter analysis
    Antiproliferative activity against human NCI-H460 cells after 72 hrs by coulter counter analysis
    [PMID: 21783369]
    NCI-H460 IC50
    0.036 μM
    Compound: 3
    Antitumor activity against human NCI-H460 cells by SRB method
    Antitumor activity against human NCI-H460 cells by SRB method
    [PMID: 19541483]
    NCI-H460 IC50
    1.18 μM
    Compound: topotecan
    Cytotoxicity against human NCI-H460 cells after 1 hr
    Cytotoxicity against human NCI-H460 cells after 1 hr
    [PMID: 18248813]
    NCI-H460 IC50
    1.18 μM
    Compound: topotecan
    Antiproliferative activity against human H460 cells after 1 hr of drug exposure measured after 72 hrs
    Antiproliferative activity against human H460 cells after 1 hr of drug exposure measured after 72 hrs
    [PMID: 18424133]
    NCI-H460 IC50
    1.38 μM
    Compound: Topotecan
    In vitro cytotoxicity against H460 a human non-small lung carcinoma cell line after 1 hour drug exposure
    In vitro cytotoxicity against H460 a human non-small lung carcinoma cell line after 1 hour drug exposure
    [PMID: 11212094]
    NCI-H460 IC50
    1.75 μM
    Compound: Topotecan
    Antiproliferative activity against human NCI-H460 cells after 1 hr by coulter counter analysis
    Antiproliferative activity against human NCI-H460 cells after 1 hr by coulter counter analysis
    [PMID: 21783369]
    NCI-H460 IC50
    110 nM
    Compound: 7
    Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay in presence of 40 mg/ml HSA
    Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay in presence of 40 mg/ml HSA
    [PMID: 21341674]
    NCI-H460 GI50
    44.67 nM
    Compound: 20
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    [PMID: 24502276]
    NCI-H460 IC50
    45 nM
    Compound: 7
    Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay
    [PMID: 21341674]
    NCI-H460 IC50
    7.1 μM
    Compound: Topotecan
    Concentration causing 50% decrease of topotecan-resistant subline (H460/TPT) cell growth over that of untreated control.
    Concentration causing 50% decrease of topotecan-resistant subline (H460/TPT) cell growth over that of untreated control.
    [PMID: 11052801]
    NCI-H460 IC50
    7.29 μM
    Compound: Top
    Antiproliferative activity against human H460 cells after 72 hrs by XTT assay
    Antiproliferative activity against human H460 cells after 72 hrs by XTT assay
    [PMID: 23237975]
    NCI-H69 IC50
    15.9 nM
    Compound: Topotecan
    Cytotoxicity measured using the H69 parental (H69/P) human small cell lung carcinoma cell line
    Cytotoxicity measured using the H69 parental (H69/P) human small cell lung carcinoma cell line
    [PMID: 11806724]
    NCI-H69 IC50
    6 nM
    Compound: 7
    Cytotoxicity against human H69 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human H69 cells after 72 hrs by alamar blue assay
    [PMID: 21341674]
    NCI-H69 IC50
    62.9 nM
    Compound: Topotecan
    Cytotoxicity measured using the drug resistant, P-glycoprotein (Pgp) expressing human small cell lung carcinoma cell line H69/LX4
    Cytotoxicity measured using the drug resistant, P-glycoprotein (Pgp) expressing human small cell lung carcinoma cell line H69/LX4
    [PMID: 11806724]
    OVCAR-3 GI50
    0.22 μM
    Compound: 2
    Growth inhibition of human OVCAR3 cells by five-dose growth inhibition assay
    Growth inhibition of human OVCAR3 cells by five-dose growth inhibition assay
    [PMID: 25909279]
    P388 IC50
    > 10 μM
    Compound: topotecan
    Cytotoxicity against camptothecin-resistant mouse P388 cells by MTT method
    Cytotoxicity against camptothecin-resistant mouse P388 cells by MTT method
    [PMID: 18771930]
    P388 IC50
    0.045 μM
    Compound: Topotecan
    Cytotoxicity against mouse P388 cells after MTT assay
    Cytotoxicity against mouse P388 cells after MTT assay
    [PMID: 18829334]
    P388 IC50
    0.045 μM
    Compound: Topotecan
    Cytotoxicity against mouse P388 cells by MTT method
    Cytotoxicity against mouse P388 cells by MTT method
    [PMID: 19012996]
    P388 IC50
    0.045 μM
    Compound: topotecan
    Cytotoxicity against mouse P388 cells by MTT method
    Cytotoxicity against mouse P388 cells by MTT method
    [PMID: 18771930]
    P388CPT45 IC50
    > 10 μM
    Compound: Topotecan
    Cytotoxicity against camptothecin-resistant and TOP1 deficient mouse P388/CPT45 cells after MTT assay
    Cytotoxicity against camptothecin-resistant and TOP1 deficient mouse P388/CPT45 cells after MTT assay
    [PMID: 18829334]
    PC-3 IC50
    0.185 μM
    Compound: 4
    Cytotoxicity against human PC3 cells expressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay
    Cytotoxicity against human PC3 cells expressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay
    [PMID: 22959246]
    PC-3 IC50
    1 μM
    Compound: Topotecan
    Antiproliferative activity against human PC3 cells by [3H]thymidine incorporation assay
    Antiproliferative activity against human PC3 cells by [3H]thymidine incorporation assay
    [PMID: 20932758]
    PC-3 GI50
    1.3 μM
    Compound: 3, TPT
    Cytotoxicity against p53-deficient human PC3 cells after 48 hrs by SRB assay
    Cytotoxicity against p53-deficient human PC3 cells after 48 hrs by SRB assay
    [PMID: 19715319]
    PC-3 IC50
    2 μM
    Compound: 3, TPT
    Cytotoxicity against p53-deficient human PC3 cells after 48 hrs by SRB assay
    Cytotoxicity against p53-deficient human PC3 cells after 48 hrs by SRB assay
    [PMID: 19715319]
    PC-3 IC50
    3.99 μM
    Compound: 2, TPT
    Cytotoxicity against human PC3 cells by MTT assay
    Cytotoxicity against human PC3 cells by MTT assay
    [PMID: 19056266]
    PC-3 IC50
    45 nM
    Compound: 7
    Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay
    [PMID: 21341674]
    PC-3 IC50
    62 nM
    Compound: Topotecan
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    [PMID: 24900725]
    PC-3 IC50
    9.35 μM
    Compound: Topotecan
    Antiproliferative activity against human PC3 cells after 72 hrs by XTT assay
    Antiproliferative activity against human PC3 cells after 72 hrs by XTT assay
    [PMID: 26686931]
    QGY-7703 IC50
    11.864 μM
    Compound: Topotecan
    Cytotoxicity in human QGY7703 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human QGY7703 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 30227711]
    RPMI 8402 IC50
    > 10 μM
    Compound: Topotecan
    Cytotoxicity using camptothecin-resistant variant of RPM18402 (CPT-K5) possessing functional, but mutant TOP-1
    Cytotoxicity using camptothecin-resistant variant of RPM18402 (CPT-K5) possessing functional, but mutant TOP-1
    [PMID: 12392745]
    RPMI 8402 IC50
    0.012 μM
    Compound: Topotecan
    Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment
    Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment
    [PMID: 12747798]
    RPMI 8402 IC50
    0.021 μM
    Compound: Topotecan
    Cytotoxicity against human RPMI8402 cells after MTT assay
    Cytotoxicity against human RPMI8402 cells after MTT assay
    [PMID: 18829334]
    RPMI 8402 IC50
    0.21 μM
    Compound: topotecan
    Cytotoxicity against human RPMI8402 cells by MTT method
    Cytotoxicity against human RPMI8402 cells by MTT method
    [PMID: 18771930]
    RPMI-8226 IC50
    0.021 μM
    Compound: Topotecan
    Cytotoxicity against human RPMI8226 cells by MTT method
    Cytotoxicity against human RPMI8226 cells by MTT method
    [PMID: 19012996]
    SF-539 GI50
    0.01 μM
    Compound: 2
    Growth inhibition of human SF539 cells by five-dose growth inhibition assay
    Growth inhibition of human SF539 cells by five-dose growth inhibition assay
    [PMID: 25909279]
    Sf9 IC50
    0.021 μM
    Compound: Topotecan
    Poison activity at recombinant human TOP1 expressed in baculovirus infected Sf9 insect cells assessed as decrease in relaxed supercoiled pBS(SK+) DNA mobility measured after 30 mins by ethidium bromide staining based agarose gel electrophoresis
    Poison activity at recombinant human TOP1 expressed in baculovirus infected Sf9 insect cells assessed as decrease in relaxed supercoiled pBS(SK+) DNA mobility measured after 30 mins by ethidium bromide staining based agarose gel electrophoresis
    [PMID: 30897325]
    SGC-7901 IC50
    > 10 μM
    Compound: Topotecan
    Cytotoxicity in human SGC7901 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human SGC7901 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 30227711]
    SGC-7901 IC50
    4.17 μM
    Compound: TPT
    Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    [PMID: 34774339]
    SK-BR-3 IC50
    8.91 μM
    Compound: Top
    Antiproliferative activity against human SKBR3 cells after 72 hrs by XTT assay
    Antiproliferative activity against human SKBR3 cells after 72 hrs by XTT assay
    [PMID: 23237975]
    SK-MEL-2 IC50
    140 nM
    Compound: 7
    Cytotoxicity against human SK-MEL-2 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human SK-MEL-2 cells after 72 hrs by alamar blue assay
    [PMID: 21341674]
    SK-N-SH IC50
    0.093 μM
    Compound: Topotecan
    Cytotoxicity in human SK-N-SH cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human SK-N-SH cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 30227711]
    SK-OV-3 IC50
    44 nM
    Compound: 3
    Human tumor cell cytotoxicity assay was performed using MTT (SK-OV3 cell line )
    Human tumor cell cytotoxicity assay was performed using MTT (SK-OV3 cell line )
    [PMID: 8576914]
    SK-OV-3 IC50
    44 nM
    Compound: Topotecan
    Cytotoxicity was determined in vitro in SK-OV-3 cells (ovarian) of human tumor cell lines by using MTT assay
    Cytotoxicity was determined in vitro in SK-OV-3 cells (ovarian) of human tumor cell lines by using MTT assay
    [PMID: 7853331]
    SK-VLB IC50
    149 nM
    Compound: Topotecan
    Cytotoxicity was determined in vitro in SKVLB cells(ovarian with upregulated MDRp-glycoprotein) of human tumor cell lines by using MTT assay
    Cytotoxicity was determined in vitro in SKVLB cells(ovarian with upregulated MDRp-glycoprotein) of human tumor cell lines by using MTT assay
    [PMID: 7853331]
    SK-VLB IC50
    150 nM
    Compound: 3
    Human tumor cell cytotoxicity assay was performed using MTT (SKVLB cell line )
    Human tumor cell cytotoxicity assay was performed using MTT (SKVLB cell line )
    [PMID: 8576914]
    SMMC-7721 IC50
    11.627 μM
    Compound: Topotecan
    Cytotoxicity in human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 30227711]
    SN12C GI50
    0.02 μM
    Compound: 2
    Growth inhibition of human SN12C cells by five-dose growth inhibition assay
    Growth inhibition of human SN12C cells by five-dose growth inhibition assay
    [PMID: 25909279]
    SW-620 IC50
    > 500 nM
    Compound: 2
    Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    [PMID: 35932565]
    SW-620 IC50
    3.2 nM
    Compound: Topotecan
    Cytotoxic potentiation of Topotecan (TP) by the compound in human colon carcinoma SW620 cell line
    Cytotoxic potentiation of Topotecan (TP) by the compound in human colon carcinoma SW620 cell line
    [PMID: 12408707]
    T47D IC50
    104 nM
    Compound: Topotecan
    Cytotoxicity was determined in vitro in T47D cells(breast) of human tumor cell lines by using MTT assay
    Cytotoxicity was determined in vitro in T47D cells(breast) of human tumor cell lines by using MTT assay
    [PMID: 7853331]
    THP-1 IC50
    1.5 μM
    Compound: 3, TPT
    Cytotoxicity against human THP1 cells expressing p53 mutant after 48 hrs by SRB assay
    Cytotoxicity against human THP1 cells expressing p53 mutant after 48 hrs by SRB assay
    [PMID: 19715319]
    U-251 EC50
    > 20 μM
    Compound: 6, TPT
    Effect on basal transcription in human U251 cells co-transfected with pGL3 incubated for 24 hrs by luciferase reporter gene assay
    Effect on basal transcription in human U251 cells co-transfected with pGL3 incubated for 24 hrs by luciferase reporter gene assay
    10.1039/C4MD00111G
    U-251 IC50
    > 3 μM
    Compound: Topotecan
    Inhibition of HIF1alpha in human U251 cells under normoxic condition by luciferase reporter gene assay
    Inhibition of HIF1alpha in human U251 cells under normoxic condition by luciferase reporter gene assay
    [PMID: 20932758]
    U-251 EC50
    0.012 μM
    Compound: 6, TPT
    Inhibition of human HIF1alpha-mediated transcription expressed in human U251 cells co-transfected with pGL2-TK-HRE incubated for 24 hrs by luciferase reporter gene assay
    Inhibition of human HIF1alpha-mediated transcription expressed in human U251 cells co-transfected with pGL2-TK-HRE incubated for 24 hrs by luciferase reporter gene assay
    10.1039/C4MD00111G
    U-251 IC50
    0.06 μM
    Compound: Topotecan
    Inhibition of HIF1alpha in human U251 cells under hypoxic condition by luciferase reporter gene assay
    Inhibition of HIF1alpha in human U251 cells under hypoxic condition by luciferase reporter gene assay
    [PMID: 20932758]
    U-251 IC50
    0.37 μM
    Compound: Topotecan
    Antiproliferative activity against human U-251 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Antiproliferative activity against human U-251 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    [PMID: 34537445]
    U-251 IC50
    0.5 μM
    Compound: Topotecan
    Antiproliferative activity against human U251 cells by [3H]thymidine incorporation assay
    Antiproliferative activity against human U251 cells by [3H]thymidine incorporation assay
    [PMID: 20932758]
    U-251 EC50
    54 nM
    Compound: 4b, NSC-609699, hycamtin
    Inhibition of topoisomerase-1 in human U251 cells assessed as inhibition of hypoxia-induced HIF-1alpha accumulation in nuclear extract after 6 to 24 hrs by immunoblot analysis
    Inhibition of topoisomerase-1 in human U251 cells assessed as inhibition of hypoxia-induced HIF-1alpha accumulation in nuclear extract after 6 to 24 hrs by immunoblot analysis
    [PMID: 22305612]
    U-251 EC50
    71.3 nM
    Compound: 4b, NSC-609699, hycamtin
    Inhibition of topoisomerase-1 in human U251 cells assessed as inhibition of HIF-1-mediated hypoxia-induced VEGF expression after 24 hrs by luciferase reporter gene assay
    Inhibition of topoisomerase-1 in human U251 cells assessed as inhibition of HIF-1-mediated hypoxia-induced VEGF expression after 24 hrs by luciferase reporter gene assay
    [PMID: 22305612]
    U-87MG ATCC IC50
    0.06 μM
    Compound: Topotecan
    Antiproliferative activity against human U-87 MG cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Antiproliferative activity against human U-87 MG cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    [PMID: 34537445]
    U-87MG ATCC IC50
    0.16 μM
    Compound: TPT
    Antiproliferative activity against human U87 cells assessed as growth inhibition after 48 hrs by MTT assay
    Antiproliferative activity against human U87 cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 24826818]
    U-937 IC50
    1.1 μM
    Compound: 3, TPT
    Cytotoxicity against human U937 cells expressing p53 mutant after 48 hrs by SRB assay
    Cytotoxicity against human U937 cells expressing p53 mutant after 48 hrs by SRB assay
    [PMID: 19715319]
    UACC-62 GI50
    0.01 μM
    Compound: 2
    Growth inhibition of human UACC62 cells by five-dose growth inhibition assay
    Growth inhibition of human UACC62 cells by five-dose growth inhibition assay
    [PMID: 25909279]
    WISH IC50
    1.3 μM
    Compound: Topotecan
    Cytotoxicity against human WISH cells after 96 hrs by MTT assay
    Cytotoxicity against human WISH cells after 96 hrs by MTT assay
    [PMID: 16792409]
    In Vitro

    Topotecan obviously inhibits proliferation of human glioma cells and glioma stem cells (GSCs) in a dose- and time-dependent manner[1].
    Topotecan (0-40 μM) obviously inhibits the cell viability compared with the control groups, in a dose-dependent manner[1].
    Topotecan shows anti-proliferation activity against U251, U87, GSCs-U251 and GSCs-U87 cells, with IC50 values of 2.73±0.25, 2.95±0.23, 5.46±0.41, and 5.95±0.24 μM, respectively[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    NUB-7 metastatic model, the animals belonging to all the 4 groups are sacrificed after 14 days treatment. Compared with the control, Low dose metronomic (LDM) Topotecan (TP) and TP+Pazopanib (PZ) liver weights are significantly lower in TP+PZ-treated animals, compared with PZ. Microscopic tumors are visible in the livers of mice belonging to all the groups except TP+PZ confirming the ability of TP+PZ to control liver metastasis[2].
    Topotecan (0.5, 1.0, and 1.5 mg/kg; Orally, daily) causes greater reduction in microvascular density in an ovarian cancer model, but the mice treated with 1.5 mg/kg daily, oral Topotecan show decreased food intake, and a lesser antitumor effect[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    421.45

    Formula

    C23H23N3O5

    CAS No.
    SMILES

    O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=C(CN(C)C)C(O)=CC=C5N=C4C3=C2)=O

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.

    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (237.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.3728 mL 11.8638 mL 23.7276 mL
    5 mM 0.4746 mL 2.3728 mL 4.7455 mL
    View the Complete Stock Solution Preparation Table
    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 2.5 mg/mL (5.93 mM); Clear solution; Need ultrasonic

      This protocol yields a clear solution of 2.5 mg/mL.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2.5 mg/mL (5.93 mM); Clear solution; Need ultrasonic

      This protocol yields a clear solution of 2.5 mg/mL.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation
    References
    Cell Assay
    [1]

    The U251, U87, GSCs-U251 and GSCs-U87 cells are seeded at a density of 2×104 cells per well in 96-well plates separately, and incubated for 24 h. Cells are administered with Shikonin and Topotecan (0.02, 0.2, 2, 20, 40 μM). After the treatment, 10 μL of cell counting kit-8 (CCK-8) is added into each well for additional 1-hour incubation at 37°C. The optical density (OD) is read with a microplate reader at 450 nm[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [2]

    Mice[2]
    For subcutaneous xenograft studies, we used SK-N-BE, SH-SY5Y, KHOS, and RH30. 1×106 cells are implanted subcutaneously into the inguinal fat pad of each of nonobese diabetic/severe combined immune deficient (NOD/SCID) mice. When tumors reached 0.5 cm in diameter, the animals are randomized into 4 groups and treated daily by oral gavage. The animals are grouped as: Control group, LDM Topotecan group or LDM TP (1 mg/kg Topotecan), Pazopanib group or PZ (150 mg/kg Pazopanib) and combination group or TP+PZ (1 mg/kg Topotecan+150 mg/kg Pazopanib). To compare pulse Topotecan with LDM TP in KHOS osteosarcoma model, PZ is replaced by weekly oral dose of pulse Topotecan (SKF104864) or Pulse TP (15 mg/kg Topotecan (SKF104864)). The criteria for endpoint are tumor sizes exceeding 2.0 cm in diameter or animals showing signs of morbidity. The tumor sizes are measured on a daily basis until the endpoint or sacrifice. The long (D) and short diameters (d) are measured with calipers. Tumor volume (cm3) is calculated as V=0.5×D×d2. When the endpoint is reached or at the end of the treatment, the animals are sacrificed by cervical dislocation.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References

    Complete Stock Solution Preparation Table

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.3728 mL 11.8638 mL 23.7276 mL 59.3190 mL
    5 mM 0.4746 mL 2.3728 mL 4.7455 mL 11.8638 mL
    10 mM 0.2373 mL 1.1864 mL 2.3728 mL 5.9319 mL
    15 mM 0.1582 mL 0.7909 mL 1.5818 mL 3.9546 mL
    20 mM 0.1186 mL 0.5932 mL 1.1864 mL 2.9660 mL
    25 mM 0.0949 mL 0.4746 mL 0.9491 mL 2.3728 mL
    30 mM 0.0791 mL 0.3955 mL 0.7909 mL 1.9773 mL
    40 mM 0.0593 mL 0.2966 mL 0.5932 mL 1.4830 mL
    50 mM 0.0475 mL 0.2373 mL 0.4746 mL 1.1864 mL
    60 mM 0.0395 mL 0.1977 mL 0.3955 mL 0.9887 mL
    80 mM 0.0297 mL 0.1483 mL 0.2966 mL 0.7415 mL
    100 mM 0.0237 mL 0.1186 mL 0.2373 mL 0.5932 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Topotecan
    Cat. No.:
    HY-13768
    Quantity:
    MCE Japan Authorized Agent: